Abstract: One or more video gateway devices configured to: access pre-configured criteria including at least a first condition, a second condition, and a first event; access video content captured by cameras configured to capture video of areas of a manufacturing facility; determine, based on an analysis of the video content, that the first condition is satisfied; access sensor data from one or more sensors; determine, based on an analysis of the sensor data, that the second condition is satisfied; and based on determining that the first and second conditions are satisfied, cause the first event to be executed.

Abstract: Systems and techniques are described for generating a color image by computationally combining chromatically undersampled and shifted information present in multiple component image frames captured via a sparse color filter array that includes a minority of wavelength-filtered picture elements and a remaining majority of panchromatic picture elements. A burst capture is initiated of multiple image frames via a color filter array comprising a plurality of subunits, each subunit including a minority of one or more wavelength-filtered adjacent pixels and a majority of remaining panchromatic pixels. Each of the multiple image frames is processed to generate a resulting color image.

Abstract: A unitary garment body having a front abdominal portion interposed between two arm openings and the two leg openings of the garment, of an elastic-based polymer material, with an inner surface, defining at least one pocket interposed between outer and inner surfaces of the front abdominal portion and configured to enclose and define a pocket cavity shaped and sized to receive a thermal pack, and with a plurality of front pressure protrusions on the pocket and each projecting inwardly from the inner surface toward the abdomen cavity, disposed in a tightly spaced configuration, each having a rounded tip, and each having a width ranging from 1-2 mm and a height relative to the inner surface of the front abdominal portion ranging from 0.2-0.5 mm and having a rear back portion interposed also of an elastic-based polymer material opposing the front abdominal portion.

Abstract: Methods of treating postherpetic neuralgia in a mammal with a pharmaceutical composition comprising a spiro-oxindole compound of the formula: are disclosed. The methods provide excellent penetration of the spiro-oxindole compound into the affected skin area to effectively reduce the severity of the postherpetic neuralgia and/or to alleviate the postherpetic neuralgia with minimal or negligible systemic exposure of the spiro-oxindole compound.

Abstract: Methods of treating postherpetic neuralgia in a mammal with a pharmaceutical composition comprising a spiro-oxindole compound of the formula: are disclosed. The methods provide excellent penetration of the spiro-oxindole compound into the affected skin area to effectively reduce the severity of the postherpetic neuralgia and/or to alleviate the postherpetic neuralgia with minimal or negligible systemic exposure of the spiro-oxindole compound.

Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.

Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.

Abstract: Methods of treating pain associated with osteoarthritis of a joint in a mammal with a pharmaceutical composition comprising a spiro-oxindole compound of the formula: are disclosed. The methods provide excellent penetration of the spiro-oxindole compound into the synovial membrane of the affected joint to effectively reduce the severity of the pain and/or to alleviate the pain with minimal or negligible systemic exposure.

Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.

Abstract: Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human include administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein.

Abstract: Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human, including administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein, and compositions including a compound of formula (I).

Abstract: Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human include administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein.

Abstract: Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human include administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein.

Abstract: Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human include administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein.

Abstract: The present invention relates to elongase genes, their polypeptides and their control regions, and the use of such genes, polypeptides and control regions in determining compositions for use in the treatment of disease. The identified compositions regulate the expression of the elongase genes or modulate the activity of their protein products. The nucleotide and amino acid sequences are taught for ELG4, ELG6 and ELG7. The control sequences and function are taught for ELG1, ELG2, ELG3, ELG4, ELG5, ELG6 and ELG7.

Abstract: The present invention relates to elongase genes, their polypeptides and their control regions, and the use of such genes, polypeptides and control regions in determining compositions for use in the treatment of disease. The identified compositions regulate the expression of the elongase genes or modulate the activity of their protein products. The nucleotide and amino acid sequences are taught for ELG4, ELG6 and ELG7. The control sequences and function are taught for ELG1, ELG2, ELG3, ELG4, ELG5, ELG6 and ELG7.

Abstract: A virtual multichannel sound system is presented to improve audio reproduction by statically or dynamically conforming signal processing to specific speaker characteristics and/or arrangements. According to one such aspect, one or more dynamic signal processing algorithms driving two or more speakers are altered in response to the relative physical characteristics or arrangements of these speakers, where parameter information for these algorithms is either factory set, user input, or automatically supplied to the processor. Examples of such relative speaker differences include speaker spacing or alignment, speaker or enclosure compliance, and enclosure configuration. Another aspect is to alter the processing algorithms in response to common speaker characteristics for certain conditions of input signals.

Abstract: The present invention relates to methods for identifying genes regulated by fat and their subsequent use in determining compositions for use in the treatment of disease, by utilizing the identified genes and their proteins. The identified compositions regulate the expression of the fat regulated genes or modulate the activity of their protein products. The nucleotide and amino acid sequences for METP, a novel mitochondrial carrier protein and FTF1, a fat responsive transcription factor, are taught. The nucleotide sequence for A1BG, a plasma glycoprotein is taught. The nucleotide and amino add sequences for human GPAT and rat GLOL are taught. Control sequences for human METP, GLOL, FTF1, SCD, GPAT and A1BG are taught.

Abstract: The present invention relates to elongase genes, their polypeptides and their control regions, and the use of such genes, polypeptides and control regions in determining compositions for use in the treatment of disease. The identified compositions regulate the expression of the elongase genes or modulate the activity of their protein products. The nucleotide and amino acid sequences are taught for ELG4, ELG6 and ELG7. The control sequences and function are taught for ELG1, ELG2, ELG3, ELG4, ELG5, ELG6 and ELG7.